TargetMol

Diethylstilbestrol dipropionate

Product Code:
 
TAR-T31450
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T31450-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T31450-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T31450-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Diethylstilbestrol dipropionate can be used in estrogen therapy of relapsed prostate cancer.
CAS:
130-80-3
Formula:
C24H28O4
Molecular Weight:
380.484
Purity:
0.98
SMILES:
CCC(=O)Oc1ccc(cc1)C(CC)=C(/CC)c1ccc(OC(=O)CC)cc1

References

1. Hsieh TF, Tseng CJ, Tang JB, Chen YH. A proline rich acidic protein PRAP identified from uterine luminal fluid of estrous mice is able to enhance the estrogen responsiveness of Ishikawa cells. J Cell Biochem. 2011 Nov;112(11):3122-8. doi: 10.1002/jcb.23238. PubMed PMID: 21695714. 2. Nakata S, Miyazawa Y, Sasaki Y, Nakano K, Takahashi H. [Prognostic factors for estrogen therapy of relapsed prostate cancer after maximal androgen blockade (MAB)]. Nihon Hinyokika Gakkai Zasshi. 2010 May;101(4):597-602. Japanese. PubMed PMID: 20535987. 3. Fujinami K, Miura T, Takizawa A, Osada Y. [Combination chemotherapy with docetaxel and cisplatin in patients with hormone-refractory prostate cancer]. Hinyokika Kiyo. 2005 Jan;51(1):5-8. Japanese. PubMed PMID: 15732332. 4. Leaf AN, Propert K, Corcoran C, Catalano PJ, Trump DL, Harris JE, Davis TE. Phase III study of combined chemohormonal therapy in metastatic prostate cancer (ECOG 3882): an Eastern Cooperative Oncology Group study. Med Oncol. 2003;20(2):137-46. PubMed PMID: 12835516.